Major pharmaceutical companies continually research and develop new medications and treatments for brain cancer, which must be shown to be safe and effective before doctors can prescribe them to patients. Through clinical trials, researchers test the effects of new medications on a group of volunteers with brain cancer. Following a strict protocol and using carefully controlled conditions, researchers evaluate the investigational drugs under development and measure the ability of the new drug to treat brain cancer, its safety, and any possible side effects.
Some patients are reluctant to take part in clinical trials for fear of getting no treatment at all for their brain cancer. This is simply not true. Patients who participate in clinical trials receive the most effective therapy currently available for their condition -- or they may receive treatments that are being evaluated for future use. These brain cancer drugs may be even more effective than the current treatment. The only way to find out which treatment is best is by comparing them head-to-head in a clinical trial.
Craniopharyngiomas are histologically benign and do not metastasize to remote brain locations or to areas outside the sellar region except by direct extension. They may be invasive, however, and may recur locally. They may be classified as adamantinomatous or squamous papillary, with the former being the predominant form in children. They are typically composed of both a solid portion with an abundance of calcification, and a cystic component which is filled with a dark, oily fluid. Recent evidence...
This web site, developed by the nonprofit Coalition of Cancer Cooperative Groups, is an unbiased cancer clinical trial matching and navigation service enabling patients to search for cancer trials based on disease and location.